Hopewell Therapeutics develops tissue-targeted lipid nanoparticles (ttLNPs) for the precise delivery of genomic medicines, addressing the challenge of effectively reaching specific tissues in patients with unmet medical needs. Their technology aims to enhance the efficacy of gene therapy and gene editing by improving the targeting and uptake of therapeutic agents.
Funding
$23.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current genomic medicines face challenges in effectively reaching specific tissues within the body, limiting their therapeutic potential and efficacy for patients with unmet medical needs. Traditional delivery methods often result in off-target effects and insufficient uptake in the intended tissues.
Solution
Hopewell Therapeutics is developing tissue-targeted lipid nanoparticles (ttLNPs) designed for the precise delivery of genomic medicines. Their technology aims to improve the targeting and uptake of therapeutic agents in specific tissues, enhancing the efficacy of gene therapy and gene editing. By optimizing the delivery mechanism, Hopewell Therapeutics seeks to minimize off-target effects and maximize the therapeutic impact of genomic medicines. This approach has the potential to unlock new treatment options for a range of diseases with high unmet medical needs.
Target Audience
The primary target audience includes patients with unmet medical needs who could benefit from more effective and targeted genomic medicines, as well as pharmaceutical companies developing gene therapies and gene editing technologies.
Features
- Tissue-targeted lipid nanoparticles (ttLNPs) for precise delivery of genomic medicines
- Enhanced targeting and uptake of therapeutic agents in specific tissues
- Optimized delivery mechanism to minimize off-target effects
- Potential to improve the efficacy of gene therapy and gene editing